Compare HCWB & DFNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCWB | DFNS |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 4.2M |
| IPO Year | 2021 | 2020 |
| Metric | HCWB | DFNS |
|---|---|---|
| Price | $0.99 | $2.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | ★ $65.00 |
| AVG Volume (30 Days) | 82.2K | ★ 555.2K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 261.46 |
| EPS | ★ N/A | N/A |
| Revenue | $4,099,750.00 | ★ $5,913,461.00 |
| Revenue This Year | $12,215.61 | N/A |
| Revenue Next Year | N/A | $33.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $1.75 |
| 52 Week High | $23.94 | $335.00 |
| Indicator | HCWB | DFNS |
|---|---|---|
| Relative Strength Index (RSI) | 29.59 | 28.60 |
| Support Level | $0.86 | N/A |
| Resistance Level | $1.28 | $7.36 |
| Average True Range (ATR) | 0.09 | 0.44 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 18.49 | 20.25 |
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. The company operates as a strategic platform, building a portfolio of mission-critical suppliers and technology companies. Its portfolio includes businesses involved in defense and aerospace technologies, such as AI software, unmanned aerial systems, electro-mechanical manufacturing, and motion control systems, as well as activities in technology distribution, licensing, and defense infrastructure development through joint ventures.